El ensayo arroja resultados positivos en el primer ensayo clínico dirigido por la industria sobre telangiectasia hemorrágica hereditaria (HHT) VAD044 mostró una seguridad y tolerabilidad favorables, junto con una eficacia exploratoria en las manifestaciones clave de la enfermedad Los…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.